News | November 10, 2023
Aurobindo Pharma posts Q2 FY 24 up 84% at Rs. 752 Cr
The company reported net profit after share of profit/loss of JV and minority interest at Rs. 752 crore vs. Rs. 409 crore in Q2FY23
The company reported net profit after share of profit/loss of JV and minority interest at Rs. 752 crore vs. Rs. 409 crore in Q2FY23
We are redesigning Bayer to focus only on what’s essential for our mission, ‘Health for all, hunger for none’”
Revenue in the three months ended on Oct. 1 also slipped by 42% to US$ 13.23 billion
India is following a holistic and inclusive approach in alignment with the vison of Universal Health Coverage and the resolute commitment to ‘leave no one behind
Impressive safety and efficacy for solid cancer patients followed by global clinical study plan
Dr Reddy’s Laboratories recorded revenue of Rs 6,880.20 crore during the quarter
The companies plan to start a pivotal Phase 3 trial in the coming months
The sBLA is supported by a usability study which confirmed that individuals over 18 years of age could self-administer
Syngene gains access to ERS Genomics' foundational CRISPR/Cas9 patent portfolio, ushering in a new era of technical innovation in India for its global partners
New Molecular biology lab launched, AIIA increased its work scope in form of MoUs
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
